ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

GMAB Genmab AS

29.73
2.01 (7.25%)
2024年5月4日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Genmab AS GMAB NASDAQ Depository Receipt
  前日比 前日比 % 現在値 時刻
2.01 7.25% 29.73 08:05:20
始値 安値 高値 終値 前日終値
29.73 29.46 29.92 29.72 27.72
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/3007:40BWFDA Grants Full Approval for TIVDAK® to Treat Recurrent or..
2024/4/0314:35BWGenmab to Broaden and Strengthen Oncology Portfolio with..
2024/3/1202:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/3/0503:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/3/0503:26EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/3/0207:04EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0101:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2901:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2806:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2721:45BWU.S. FDA Accepts for Priority Review the Supplemental..
2024/2/2702:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2700:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2306:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/2/2101:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/1505:42EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/1503:49EDGAR2Form 20-F - Annual and transition report of foreign private..
2024/2/1502:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/0220:45BWTisotumab Vedotin Marketing Authorization Application..
2024/2/0101:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/2323:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0921:45DJNPfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval
2024/1/0920:45BWTIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics..
2024/1/0322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1401:46EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1002:00BWNew Pivotal Data for Bispecific Antibody Epcoritamab..
2023/12/0203:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/2721:00BWGenmab Announces Positive Regulatory Updates for Epcoritamab..
2023/11/2206:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/1000:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0902:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0801:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0222:05BWGenmab Announces Multiple Abstracts to be Presented at the..
2023/10/2223:30BWTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged..
2023/10/1721:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/0523:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/2905:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/2521:53EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/2521:50DJNAbbVie, Genmab Get Conditional Europe OK of Tepkinly..
2023/9/2520:45BWGenmab Announces European Commission Approval of TEPKINLY®..
2023/9/2518:55BWEPKINLY™ (epcoritamab) Approved by Japan Ministry of Health,..
2023/9/1322:59EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/1304:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/0522:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/0504:00BWSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv)..
2023/8/1702:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/8/1604:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/8/0400:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/2122:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/2117:30BWGenmab Announces AbbVie Receives Positive CHMP Opinion for..
2023/7/2022:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

最近閲覧した銘柄

Delayed Upgrade Clock